公开(公告)号：US20120122957A1

公开(公告)日：2012-05-17

申请号：US13264939

申请日：2010-04-19

Applicant: Andrews Dillin ,  Jennie Durieux

Inventor： Andrews Dillin ,  Jennie Durieux

IPC: A61K31/713 ,  A61P43/00 ,  G01N33/48

CPC classification number: A61K31/713 ,  C07K14/43545 ,  C12N15/113

Abstract: The invention relates to the field of longevity enhancement. More particularly, the invention provides compositions and methods relating to modulation of mitochondrial function. In certain embodiments, the invention provides methods and related compositions for the enhancement of longevity in an animal, comprising inhibition of one or more electron transport chain components, such as cco-1 and homologs thereof, in a tissue-specific manner in the animal.

Abstract translation: 本发明涉及长寿增强领域。 更具体地，本发明提供了与调节线粒体功能有关的组合物和方法。 在某些实施方案中，本发明提供用于增强动物寿命的方法和相关组合物，包括在动物中以组织特异性方式抑制一种或多种电子传递链组分，例如cco-1及其同系物。

公开(公告)号：US20100273274A1

公开(公告)日：2010-10-28

申请号：US12709831

申请日：2010-02-22

Applicant: Joseph Alan DENT ,  Igor PUTRENKO

Inventor： Joseph Alan DENT ,  Igor PUTRENKO

IPC: G01N33/68

CPC classification number: A01N61/00 ,  A61K38/00 ,  C07H21/02 ,  C07K14/43545 ,  G01N33/6872 ,  G01N2500/02

Abstract: The invention relates to novel polynucleotides which encode novel polypeptides that are acetylcholine-gated chloride channel subunits and immunogenic or acetylcholine-binding fragments thereof. The novel polypeptides may be used for identifying compounds that modulate the acetylcholine-gated chloride channels, e.g. for use as pesticides and antiparasitic agents. Methods for identifying compounds that modulate the acetylcholine-gated chloride channels are provided.

Abstract translation: 本发明涉及编码新乙酰胆碱门控氯化物通道亚基和其免疫原性或乙酰胆碱结合片段的新型多核苷酸。 新型多肽可用于鉴定调节乙酰胆碱门控氯化物通道的化合物，例如， 用作农药和抗寄生虫剂。 提供了鉴定调节乙酰胆碱门控氯通道的化合物的方法。

公开(公告)号：US07794957B2

公开(公告)日：2010-09-14

申请号：US11282262

申请日：2005-11-18

Applicant: Cynthia Kenyon ,  Javier Apfeld ,  Andrew Dillin ,  Delia Garigan ,  Ao-Lin A. Hsu ,  Josh Lehrer-Graiwer ,  Coleen Murphy

Inventor： Cynthia Kenyon ,  Javier Apfeld ,  Andrew Dillin ,  Delia Garigan ,  Ao-Lin A. Hsu ,  Josh Lehrer-Graiwer ,  Coleen Murphy

IPC: G01N33/567 ,  G01N33/53 ,  C12N5/00 ,  A01N61/00 ,  C07K1/00

CPC classification number: C12N15/111 ,  A01K67/0336 ,  A01K2217/05 ,  A01K2217/075 ,  C07K14/43545 ,  C12N2310/14 ,  C12N2320/12 ,  C12N2330/31 ,  C12Q1/26 ,  C12Q1/32 ,  C12Q1/34 ,  C12Q1/527 ,  C12Q1/533 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N2500/10

Abstract: The present invention relates to regulation of adult lifespan in eukaryotes. More particularly, the present invention is directed to methods of assaying for activators of the heat shock factor 1 (HSF-1) protein, which increases lifespan when overexpressed in an organism.

Abstract translation: 本发明涉及真核生物中成人寿命的调节。 更具体地，本发明涉及测定热休克因子1（HSF-1）蛋白的激活剂的方法，其增加在生物体中过表达时的寿命。

公开(公告)号：US07572949B2

公开(公告)日：2009-08-11

申请号：US10560563

申请日：2004-06-14

Applicant: T. Keith Blackwell ,  Jae Hyung An

Inventor： T. Keith Blackwell ,  Jae Hyung An

IPC: A01K67/00 ,  A01K67/033 ,  A61K49/00

CPC classification number: C07K14/43545 ,  C07K2319/60 ,  G01N33/5085

Abstract: The present invention relates, in part, to the C. elegans SKN-1 gene and protein (a transcription factor), and target genes thereof. The invention includes various therapeutic methods and screening methods for identifying antioxidants.

Abstract translation: 本发明部分涉及秀丽隐杆线虫SKN-1基因和蛋白质（转录因子）及其靶基因。 本发明包括用于鉴定抗氧化剂的各种治疗方法和筛选方法。

公开(公告)号：US20080305543A1

公开(公告)日：2008-12-11

申请号：US11710152

申请日：2007-02-22

Applicant: Craig C. Mello ,  Andrew Fire ,  Hiroaki Tabara ,  Alla Grishok

Inventor： Craig C. Mello ,  Andrew Fire ,  Hiroaki Tabara ,  Alla Grishok

IPC: C12N5/06 ,  C07H21/02 ,  C07K14/00 ,  C07K16/18

CPC classification number: C12N15/67 ,  C07K14/43545

Abstract: Genes involved in double-stranded RNA interference (RNAi pathway genes) are identified and used to investigate the RNAi pathway. The genes and their products are also useful for modulating RNAi pathway activity.

Abstract translation: 鉴定涉及双链RNA干扰基因（RNAi途径基因）并用于研究RNAi途径。 基因及其产物也可用于调节RNAi通路活性。

公开(公告)号：US20080254475A1

公开(公告)日：2008-10-16

申请号：US12131981

申请日：2008-06-03

Applicant: Marius HOENER ,  Giuseppe CASSATA ,  Wolfgang LINK ,  Ralf BAUMEISTER ,  Karlheinz TOVAR

Inventor： Marius HOENER ,  Giuseppe CASSATA ,  Wolfgang LINK ,  Ralf BAUMEISTER ,  Karlheinz TOVAR

IPC: C12Q1/68 ,  A01K67/033 ,  C12N15/63 ,  C12N5/06 ,  C07K14/435

CPC classification number: C12N9/93 ,  A01K67/0336 ,  A01K2217/05 ,  A01K2217/075 ,  C07K14/43545 ,  C07K2319/00

Abstract: The invention relates to nematodes as model organisms for the investigation of neurodegenerative diseases, in particular, Parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene, From C elegans, which is homologous to the human parkin gene associated with Parkinsons disease. The invention further relates to those nematodes which contain an aberrant or missing expression of at least one gene, preferably a parkin gene and/or a α-synucleine gene, which is connected with Parkinsons disease. According to the invention, the above organisms can be used for the identification and characterization of medicaments for the treatment of said disease states.

Abstract translation: 本发明涉及线虫作为用于研究神经变性疾病的模型生物，特别是帕金森病，用于发现可用于治疗上述疾病状态和鉴定线虫基因的物质和基因的用途和方法， 来自线虫，其与与帕金森病相关的人类parkin基因同源。 本发明还涉及含有与帕金森病相关的至少一种基因，优选帕金蛋白基因和/或α-突触核蛋白基因的异常或缺失表达的那些线虫。 根据本发明，上述生物体可用于鉴定和表征用于治疗所述疾病状态的药物。

公开(公告)号：US20080213798A1

公开(公告)日：2008-09-04

申请号：US11871255

申请日：2007-10-12

Applicant: Kaj GRANDIEN ,  Jonathan ROTHBLATT ,  Paola CONCARI ,  Isabelle QUELO ,  Bert KLEBL

Inventor： Kaj GRANDIEN ,  Jonathan ROTHBLATT ,  Paola CONCARI ,  Isabelle QUELO ,  Bert KLEBL

IPC: G01N33/567 ,  C07K14/00 ,  C12N9/12 ,  G01N33/53

CPC classification number: C12N15/1137 ,  A01K67/0336 ,  A01K2217/075 ,  A01K2227/703 ,  A01K2267/0331 ,  C07K14/43545 ,  C12N9/1205 ,  C12N2310/14

Abstract: The invention refers to a novel C. elegans p21-activated kinase gene, the pak-3 gene, and associated loss-of-function phenotypes. These phenotypes can be used to elucidate PAK signaling pathways in C. elegans and to screen compounds that modulate PAK signaling.

Abstract translation: 本发明涉及一种新颖的秀丽隐杆线虫p21激活的激酶基因，pak-3基因和相关的功能丧失表型。 这些表型可用于阐明秀丽隐杆线虫中的PAK信号通路，并筛选调节PAK信号传导的化合物。

公开(公告)号：US07411054B2

公开(公告)日：2008-08-12

申请号：US11445606

申请日：2006-06-02

Applicant: Rachel E. Meyers ,  Mark J. Williamson

Inventor： Rachel E. Meyers ,  Mark J. Williamson

IPC: C12N15/54 ,  C12N9/12 ,  C12N15/74 ,  C12N15/79

CPC classification number: C07K14/705 ,  A01K2217/05 ,  A61K38/00 ,  C07K14/395 ,  C07K14/43545 ,  C07K14/43581 ,  C07K14/43595 ,  C07K14/463 ,  C07K14/465 ,  C07K14/47 ,  C07K2319/00 ,  C12N9/00 ,  C12N9/0071 ,  C12N9/0083 ,  C12N9/1205 ,  C12N9/18 ,  C12N9/20 ,  C12N9/88 ,  C12N2310/3513 ,  C12Y207/01001 ,  C12Y301/04003

Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract translation: 本发明提供分离的核酸分子，命名为25869,25934,26335,50516,21117,38692,46508,16816,16839,49937,49931和49933核酸分子。 本发明还提供反义核酸分子，包含25869,25934,26335,50521,21117,38692,46508,16816,16839,4467,49931或49933核酸分子的重组表达载体，已经引入了表达载体的宿主细胞 ，以及引入或破坏25869,25934,26335,50365,21117,38692,46508,16816,16839,49937,49931或49933基因的非人类转基因动物。 本发明还进一步提供了分离的25869,2593,26335,50365,21117,38692,46508,16816,16839,49937,49931或49933蛋白，融合蛋白，抗原肽和抗-25869,25934,26335,50365,211117,38692 ，46508,16816,16839,49937,49931或49933抗体。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：US20070293450A1

公开(公告)日：2007-12-20

申请号：US11782116

申请日：2007-07-24

Applicant: Ralf BAUMEISTER ,  Bernard LAKOWSKI ,  Stefan EIMER

Inventor： Ralf BAUMEISTER ,  Bernard LAKOWSKI ,  Stefan EIMER

IPC: A61K31/7052 ,  A01K67/027 ,  C07H21/02 ,  C07H21/04 ,  C07K14/00 ,  C07K16/00 ,  C12N15/63 ,  C12Q1/02

CPC classification number: C07K14/43545 ,  A01K2217/05 ,  A01K2217/075 ,  A61K38/00

Abstract: The invention relates to isolated nucleic acid molecules coding for SES-3 proteins or muted SES-3 proteins, and vectors and transgenic organisms containing such nucleic acid molecules. The invention also relates to uses of such nucleic acid molecules or others which are functionally similar, for producing pharmaceuticals and for producing model organisms. The invention further relates to the corresponding SES-3 proteins and muted SES-3 proteins, and the antibodies induced thereby. Finally, the invention relates to the use of substances which increase the expression of human presenilin, for the treatment of Alzheimer's disease, in addition to said substances themselves and pharmaceutical compositions containing the same.

Abstract translation: 本发明涉及编码SES-3蛋白或微卫星SES-3蛋白的分离的核酸分子以及含有这种核酸分子的载体和转基因生物。 本发明还涉及功能上类似的核酸分子或其它用于生产药物和用于产生模型生物体的用途。 本发明还涉及相应的SES-3蛋白和SST-3蛋白，以及由此诱导的抗体。 最后，本发明涉及除了所述物质本身和含有它们的药物组合物外，本发明涉及增加人类早老素表达的物质用于治疗阿尔茨海默病的用途。

公开(公告)号：US07150971B2

公开(公告)日：2006-12-19

申请号：US10153398

申请日：2002-05-21

Applicant: Joel H. Rothman ,  Erin Newman-Smith ,  Gina Broitman-Maduro

Inventor： Joel H. Rothman ,  Erin Newman-Smith ,  Gina Broitman-Maduro

IPC: G01N33/53 ,  A61K39/00 ,  C07K1/00

CPC classification number: G01N33/5023 ,  A01K67/0336 ,  A01K2217/05 ,  A01K2227/703 ,  A01K2267/03 ,  C07K14/43545 ,  C07K14/721 ,  C07K2319/41 ,  C12N2830/002 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/6875 ,  G01N33/743 ,  G01N2333/4353 ,  G01N2333/70567 ,  G01N2500/10

Abstract: This invention pertains to the discovery that DPR-1 encodes a putative nuclear hormone receptor (NHR) that, based on gene reporter studies, is expressed in the endoderm throughout the life of the worm. NHR family members are transcriptional regulators that are activated when bound to their small lipophilic ligands such as steroids. While some NHRs are localized to the nucleus, others are cytoplasmic in the absence of ligand and translocate to the nucleus upon ligand binding. Once in the nucleus, they bind target sequences and regulate gene expression.